Short Interest in Bioxytran, Inc. (OTCMKTS:BIXT) Declines By 99.1%

by · The Cerbat Gem

Bioxytran, Inc. (OTCMKTS:BIXT – Get Free Report) was the recipient of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 100 shares, a drop of 99.1% from the September 30th total of 11,600 shares. Based on an average daily trading volume, of 89,700 shares, the short-interest ratio is currently 0.0 days.

Bioxytran Stock Performance

BIXT opened at $0.09 on Friday. The business’s 50-day simple moving average is $0.10 and its 200-day simple moving average is $0.11. Bioxytran has a one year low of $0.07 and a one year high of $0.18. The stock has a market capitalization of $16.34 million, a P/E ratio of -3.07 and a beta of -0.89.

About Bioxytran

(Get Free Report)

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.

Featured Stories